Alkermes plc. Interest Paid, Excluding Capitalized Interest, Operating Activities
Alkermes plc. (ALKS) reported Interest Paid, Excluding Capitalized Interest, Operating Activities of $23.01 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaidNet · last filed 2026-02-25
- Alkermes plc. interest paid, excluding capitalized interest, operating activities for fiscal 2024 was $23.01M, a 1.15% increase from fiscal 2023.
- Alkermes plc. interest paid, excluding capitalized interest, operating activities for fiscal 2023 was $22.75M, a 67.72% increase from fiscal 2022.
- Alkermes plc. interest paid, excluding capitalized interest, operating activities for fiscal 2022 was $13.56M, a 96.45% increase from fiscal 2021.
- Alkermes plc. interest paid, excluding capitalized interest, operating activities for fiscal 2021 was $6.90M, a 16.70% decline from fiscal 2020.
| Period end | Interest Paid, Excluding Capitalized Interest, Operating Activities 12 month |
|---|---|
| 2024-12-31 | $23.01M 10-K · filed 2026-02-25 |
| 2023-12-31 | $22.75M 10-K · filed 2026-02-25 |
| 2022-12-31 | $13.56M 10-K · filed 2025-02-12 |
| 2021-12-31 | $6.90M 10-K · filed 2024-02-21 |
| 2020-12-31 | $8.29M 10-K · filed 2023-02-16 |
| 2019-12-31 | $13.25M 10-K · filed 2022-02-16 |
| 2018-12-31 | $12.53M 10-K · filed 2021-02-11 |
| 2017-12-31 | $11.14M 10-K · filed 2020-02-13 |
| 2016-12-31 | $12.46M 10-K · filed 2019-02-15 |
| 2015-12-31 | $12.32M 10-K · filed 2018-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |